FGF1 alleviates LPS-induced acute lung injury via suppression of inflammation and oxidative stress

Mol Med. 2022 Jun 28;28(1):73. doi: 10.1186/s10020-022-00502-8.

Abstract

Background: Acute lung injury (ALI) and its severe form, acute respiratory distress syndrome (ARDS), are devastating clinical disorders with high mortality, and for which more effective therapies are urgently needed. FGF1, the prototype member of the FGF family, is shown to exert protective effects against injurious stimuli in multiple disease models. Here we aimed to evaluate whether FGF1 pretreatment is protective against LPS-induced ALI and elucidate the potential underlying mechanisms.

Methods: For drug-treated groups, C57B/6 mice received a single i.p. injection of FGF1 (1 mg/kg) 1 h before the LPS challenge or not. To induce the ALI model, the mice were treated by intratracheal instillation of LPS (5 mg/kg). Then, histopathological changes in lung tissues were assessed by hematoxylin and eosin staining and transmission electron microscopy. ELISA and qPCR assays were used to detect pro-inflammatory cytokine levels in BALF and lung tissues, respectively. The total number of inflammatory cells (neutrophils and macrophages) in BALF were counted using the Wright-Giemsa method. The expressions of reactive oxygen species (ROS) and malondialdehyde (MDA) were measured using their respective kits. Western blot and immunostaining were used to evaluate the expressions of antioxidants (Nrf-2, HO-1, SOD2, GPX4, and Catalase), as well as the inflammatory and/or apoptosis-related factors (TLR4, NF-κB, and Cleaved- caspase 3).

Results: FGF1 pretreatment significantly ameliorated the LPS-induced histopathological changes, reduced lung wet/dry ratios, ROS and MDA levels, total BALF protein, inflammatory cell infiltration, proinflammatory cytokine levels, and significantly increased the expression of antioxidant proteins (Nrf-2, HO-1, Catalase, and SOD2). In addition, FGF1 pretreatment significantly reduced the expression of TLR4 and cleaved- caspase 3, inhibited NF-κB activation, and reduced LPS-induced cell apoptosis.

Conclusions: Altogether, our results suggest that FGF1 pretreatment is protective against LPS-induced ALI through mediating anti-inflammatory and antioxidant effects, which may be attributed to the downregulation of TLR4 expression and inhibition of NF-κB activation, as well as promotion of antioxidant defenses. Therefore, FGF1 administration may prove beneficial in preventative strategies for ALI/ARDS.

Keywords: Acute lung injury; FGF1; Inflammation; Lipopolysaccharide; NF-κB; Nrf2; Oxidative stress; TLR4.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Lung Injury* / chemically induced
  • Acute Lung Injury* / drug therapy
  • Acute Lung Injury* / metabolism
  • Animals
  • Antioxidants / metabolism
  • Antioxidants / pharmacology
  • Caspase 3 / metabolism
  • Catalase / metabolism
  • Catalase / therapeutic use
  • Cytokines / metabolism
  • Fibroblast Growth Factor 1 / metabolism
  • Fibroblast Growth Factor 1 / pharmacology*
  • Inflammation / drug therapy
  • Inflammation / pathology
  • Lipopolysaccharides / adverse effects
  • Mice
  • NF-kappa B / metabolism
  • Oxidative Stress
  • Reactive Oxygen Species
  • Respiratory Distress Syndrome*
  • Toll-Like Receptor 4 / metabolism

Substances

  • Antioxidants
  • Cytokines
  • Lipopolysaccharides
  • NF-kappa B
  • Reactive Oxygen Species
  • Toll-Like Receptor 4
  • Fibroblast Growth Factor 1
  • Catalase
  • Caspase 3